newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's EBDTM